ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purp…

Lupus Nephritis (LN)Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV+5 more

~Estimated

~$10 – $6,250

Hospital for Special Surgery, New YorkNCT07107659

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Rheumatic DiseasesAdult Onset Still DiseaseAnkylosing Spondylitis+17 more

~Estimated

~$10 – $750

Yale UniversityNCT04402086

Phase 1

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommende…

Autoimmune DisordersSystemic SclerosisSystemic Lupus Erythematosus+2 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06434363

← PreviousPage 7 of 7Next →